Diphenyl diselenide ameliorates behavioral and oxidative parameters in an animal model of mania induced by ouabain

被引:29
作者
Bruening, Cesar Augusto [1 ]
Prigol, Marina [1 ]
Luchese, Cristiane [1 ]
Pinton, Simone [1 ]
Nogueira, Cristina Wayne [1 ]
机构
[1] Univ Fed Santa Maria, Lab Sintese Reatividade & Avaliacao Farmacol & To, Ctr Ciencias Nat & Exatas, BR-97105900 Santa Maria, RS, Brazil
关键词
Bipolar disorder; Ouabain; Oxidative stress; Organoselenium; Selenium; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; ANTIDEPRESSANT-LIKE; LIPID-PEROXIDATION; BIPOLAR DISORDER; STRESS; LITHIUM; ANTIOXIDANT; ACID; MOOD;
D O I
10.1016/j.pnpbp.2012.03.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Bipolar disorder (BD) is a common and severe mood disorder associated with higher rates of suicide and disability. Ouabain, a Na+/K+-ATPase inhibitor, induces behavioral changes in rats and has been used as a model of mania. The aim of this study was to investigate if diphenyl diselenide [(PhSe)(2)] an organoselenium compound with pharmacological properties, is effective against ouabain-induced hyperactivity and alterations in cerebral oxidative status of rats. Male Wistar rats were treated with a single dose of (PhSe)(2) (50 mg/kg, p.o.) 30 min before i.c.v, injection of ouabain (5 mu l, 10(-5) M) or with the mood stabilizer, lithium chloride (LiCl) (45 mg/kg, p.o.), twice a day, for 7 days before the administration of ouabain. Open-field locomotion was quantified after ouabain administration. Thiobarbituric acid reactive substances (TBARS), oxidatively modified proteins, tyrosine nitration, ascorbic acid and non-protein thiols (NPSH) levels and superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GR) activities were determined in the whole brain. Ouabain increased locomotor activity in the open-field test and pretreatment with (PhSe)(2) or LiCl blocked this effect. In addition, ouabain increased lipid peroxidation and oxidatively modified proteins, demonstrated by a significant increase in TBARS levels and carbonyl content, which were attenuated by pretreatment with (PhSe)(2) or LiCl. The activities of SOD and CAT were increased by ouabain. LiCl was effective on preventing the increases of both enzyme activities, but (PhSe)(2) attenuated the ouabain effect in SOD activity. GPx and GR activities, ascorbic acid, NPSH and tyrosine nitration levels were not altered in all experimental groups. Similarly to LiCI, (PhSe)(2) produced an antimanic-like action, since it was effective against the locomotor hyperactivity elicited by ouabain. The results also indicated that (PhSe)(2) was effective against oxidative stress caused by ouabain in rats. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 67 条
[1]  
Andreazza AC, 2009, J PSYCHIATR NEUROSCI, V34
[2]  
[Anonymous], 1984, METHOD ENZYMOL
[3]  
[Anonymous], 1986, SELENIUM REAGENTS IN
[4]   Medical progress: Bipolar disorder [J].
Belmaker, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :476-486
[5]   Selenium intake, mood and other aspects of psychological functioning [J].
Benton, D .
NUTRITIONAL NEUROSCIENCE, 2002, 5 (06) :363-374
[6]   Glutamate receptors modulate oxidative stress in neuronal cells. A mini-review. [J].
Boldyrev, A ;
Bulygina, E ;
Makhro, A .
NEUROTOXICITY RESEARCH, 2004, 6 (7-8) :581-587
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain [J].
Brocardo, Patricia S. ;
Budni, Josiane ;
Pavesi, Eloisa ;
Franco, Jeferson L. ;
Uliano-Silva, Marcela ;
Trevisan, Rafael ;
Terenzi, Mariana G. ;
Dafre, Alcir L. ;
Rodrigues, Ana Lucia S. .
BIPOLAR DISORDERS, 2010, 12 (04) :414-424
[9]   Evidence for the involvement of μ-opioid and δ-opioid receptors in the antinociceptive effect caused by oral administration of m-trifluoromethyl-diphenyl diselenide in mice [J].
Bruening, Cesar Augusto ;
Prigol, Marina ;
Roehrs, Juliano Alex ;
Zeni, Gilson ;
Nogueira, Cristina Wayne .
BEHAVIOURAL PHARMACOLOGY, 2010, 21 (07) :621-626
[10]  
CARLBERG I, 1985, METHOD ENZYMOL, V113, P484